Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Strikes Deal to Develop CDx for Incyte's Cancer Drugs

NEW YORK (GenomeWeb News) – Roche's Ventana Medical Systems today announced a collaboration to develop companion diagnostics for Incyte's oncology drug programs.

The first test will be developed for Incyte's ID01 inhibitor program, Ventana said, adding it will support Incyte's efforts using its expertise in companion diagnostics, immunohistochemistry technology platforms, and customer support.

Financial and other terms of the deal were not disclosed.

"With the advancement of INCB24360 into multiple Phase II studies, our first-in-class IDO1 inhibitor program was a logical place to begin to incorporate potential companion diagnostics," Victor Sandor, Incyte's group vice president, clinical development, said in a statement.

The agreement follows a deal between Ventana and Boehringer Ingelheim to develop companion diagnostics for cancer drugs in the German drug firm's pipeline. In September, Chinese regulators approved Ventana's ALK immunohistochemistry assay as a companion diagnostic for Pfizer's Xalkori (crizotinib) therapy.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.